Company collaborating with third parties using "proprietary artificial intelligence and machine learning technologies to identify nonspecific responses and understand and predict susceptibility to ...
24mon MSN
Vistagen advances PALISADE-4 trial with $61.8M in cash while refining placebo mitigation strategies
Q3 2026 Management View Shawn Singh, President and CEO, highlighted the completion of the randomized portion of the PALISADE-3 Phase III trial in social anxiety disorder as a key milestone, stating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results